Interviews

Emily Rees

2026-02-25

Countries need to shift trading partners quickly to ensure food security and maintain export markets. Diversification in export and import markets is what trade ministers focus on, and aligning trading standards with international standards is one of the main ways to get there.

César Barros

CEO

Centro de Tecnologia Canavieira (CTC)

2026-02-25

Over the past 20 years in Brazil, corn yields doubled, soybean yields increased by almost 40%, and sugarcane yields grew just 3% on average. The limitation is not technology. But how slowly sugarcane is planted and scaled, which is why we are investing heavily in seed technologies.

Warren Stone

President & COO

NeoGenomics

2026-02-24

The goal is to deliver actionable solutions to our target customers much faster. This structure has resulted in a flatter organization with less hierarchy, which we believe will enable us to accelerate decision-making going forward.

Deborah Bitterfield

CEO & Founder

Lindy Biosciences

2026-02-24

As a company, we stay focused on the formulation development piece of a product. We collaborate with pharma that brings us the molecule, and then we collaborate with a CDMO to run our process and produce clinical materials.

Doug Edgeton

President & CEO

North Carolina Biotechnology Center (NCBiotech)

2026-02-24

Research Triangle Park remains a major hub, covering around 7,000 acres, with roughly 70 percent of companies focused on life sciences or related fields.

Frank Watanabe

President & CEO

Arcutis Biotherapeutics

2026-02-23

Two years is a short time frame, but I think we’ll have continued to grow ZORYVE and will probably be generating significant cash flows that we can reinvest back into the business.

Alessandro Maselli

President & CEO

Catalent

2026-02-23

Catalent’s largest development and manufacturing footprint is in the U.S., covering nearly all our core technologies. Repatriating through CDMOs is faster, safer, and far more capital-efficient—crucial if we want to make medicines more affordable and accessible. We are already doing that work and look forward to more visibility and recognition in Washington of the role our industry is playing.

Sarah Kennedy

Founder & CEO

Calocurb

2026-02-23

We have just unblinded and got the top-line results of our fourth human clinical, which was on long-term weight loss, and they were great. We will be able talk about them when the study is published hopefully in April.

Lisa Moneymaker

Chief Strategy Officer

Medidata Solutions

2026-02-23

The rise of AI is the true catalyst, disrupting traditional business models, especially for CROs that have historically been manpower-based. As automation scales, CROs are turning to technology to differentiate their services and maintain competitiveness.

Mark Dunoyer

CEO

Alexion, AstraZeneca Rare Disease

2026-02-23

Accurate and timely diagnosis remains one of the biggest challenges in rare disease. While we previously referenced a misdiagnosis rate of around 25%, the data we work with today suggest the figure is closer to 40%, meaning nearly one in two patients is initially misdiagnosed.

Pagina 15 din 224